...
search icon
nbix-img

Neurocrine Biosciences Inc, Common Stock

NBIX

NSQ

$100.1

+$3.94

(4.1%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$9.51B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
29.228
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.17M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.33
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$84.23 L
$157.98 H
$100.1

About Neurocrine Biosciences Inc, Common Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNBIXSectorS&P500
1-Week Return5.06%-1.78%-1%
1-Month Return-10.22%-7.14%-5.24%
3-Month Return-29.47%-3.43%-9.21%
6-Month Return-15.42%-11.08%-7.68%
1-Year Return-24.73%-1.72%6.77%
3-Year Return2.88%-0.6%22.73%
5-Year Return5.12%38.04%92.61%
10-Year Return129.53%84.35%156.23%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.05B1.13B1.49B1.89B2.36B[{"date":"2020-12-31","value":44.41,"profit":true},{"date":"2021-12-31","value":48.13,"profit":true},{"date":"2022-12-31","value":63.21,"profit":true},{"date":"2023-12-31","value":80.12,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue10.10M14.30M23.20M39.70M34.00M[{"date":"2020-12-31","value":25.44,"profit":true},{"date":"2021-12-31","value":36.02,"profit":true},{"date":"2022-12-31","value":58.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.64,"profit":true}]
Gross Profit1.04B1.12B1.47B1.85B2.32B[{"date":"2020-12-31","value":44.62,"profit":true},{"date":"2021-12-31","value":48.21,"profit":true},{"date":"2022-12-31","value":63.13,"profit":true},{"date":"2023-12-31","value":79.58,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin99.03%98.74%98.44%97.90%98.56%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.7,"profit":true},{"date":"2022-12-31","value":99.4,"profit":true},{"date":"2023-12-31","value":98.85,"profit":true},{"date":"2024-12-31","value":99.52,"profit":true}]
Operating Expenses708.30M911.40M1.22B1.60B1.75B[{"date":"2020-12-31","value":40.46,"profit":true},{"date":"2021-12-31","value":52.06,"profit":true},{"date":"2022-12-31","value":69.48,"profit":true},{"date":"2023-12-31","value":91.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income318.90M196.90M249.00M250.90M570.50M[{"date":"2020-12-31","value":55.9,"profit":true},{"date":"2021-12-31","value":34.51,"profit":true},{"date":"2022-12-31","value":43.65,"profit":true},{"date":"2023-12-31","value":43.98,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(89.10M)(26.90M)(42.20M)76.60M6.50M[{"date":"2020-12-31","value":-116.32,"profit":false},{"date":"2021-12-31","value":-35.12,"profit":false},{"date":"2022-12-31","value":-55.09,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":8.49,"profit":true}]
Pre-Tax Income106.70M101.40M213.90M332.10M486.00M[{"date":"2020-12-31","value":21.95,"profit":true},{"date":"2021-12-31","value":20.86,"profit":true},{"date":"2022-12-31","value":44.01,"profit":true},{"date":"2023-12-31","value":68.33,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes(300.60M)11.80M59.40M82.40M144.70M[{"date":"2020-12-31","value":-207.74,"profit":false},{"date":"2021-12-31","value":8.15,"profit":true},{"date":"2022-12-31","value":41.05,"profit":true},{"date":"2023-12-31","value":56.95,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes407.30M89.60M154.50M249.70M341.30M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":61.31,"profit":true},{"date":"2024-12-31","value":83.8,"profit":true}]
Income From Continuous Operations407.30M89.60M154.50M191.00M341.30M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":46.89,"profit":true},{"date":"2024-12-31","value":83.8,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income407.30M89.60M154.50M249.70M341.30M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":61.31,"profit":true},{"date":"2024-12-31","value":83.8,"profit":true}]
EPS (Diluted)1.301.321.532.423.98[{"date":"2020-12-31","value":32.66,"profit":true},{"date":"2021-12-31","value":33.17,"profit":true},{"date":"2022-12-31","value":38.44,"profit":true},{"date":"2023-12-31","value":60.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NBIX
Cash Ratio 2.12
Current Ratio 3.40
Quick Ratio 3.28

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NBIX
ROA (LTM) 10.46%
ROE (LTM) 14.16%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NBIX
Debt Ratio Lower is generally better. Negative is bad. 0.30
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.70

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NBIX
Trailing PE 29.23
Forward PE 19.34
P/S (TTM) 4.04
P/B 3.67
Price/FCF 40
EV/R 3.78
EV/Ebitda 13.90
PEG 0.27

FAQs

What is Neurocrine Biosciences Inc share price today?

Neurocrine Biosciences Inc (NBIX) share price today is $100.1

Can Indians buy Neurocrine Biosciences Inc shares?

Yes, Indians can buy shares of Neurocrine Biosciences Inc (NBIX) on Vested. To buy Neurocrine Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NBIX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Neurocrine Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Neurocrine Biosciences Inc (NBIX) via the Vested app. You can start investing in Neurocrine Biosciences Inc (NBIX) with a minimum investment of $1.

How to invest in Neurocrine Biosciences Inc shares from India?

You can invest in shares of Neurocrine Biosciences Inc (NBIX) via Vested in three simple steps:

  • Click on Sign Up or Invest in NBIX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Neurocrine Biosciences Inc shares
What is Neurocrine Biosciences Inc 52-week high and low stock price?

The 52-week high price of Neurocrine Biosciences Inc (NBIX) is $157.98. The 52-week low price of Neurocrine Biosciences Inc (NBIX) is $84.23.

What is Neurocrine Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Neurocrine Biosciences Inc (NBIX) is 29.228

What is Neurocrine Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Neurocrine Biosciences Inc (NBIX) is 3.67

What is the Market Cap of Neurocrine Biosciences Inc?

The market capitalization of Neurocrine Biosciences Inc (NBIX) is $9.51B

What is Neurocrine Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Neurocrine Biosciences Inc is NBIX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top